Certolizumab
- Level
- Commodity
- Parent
- 51202400
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51202405This classification denotes a monoclonal antibody, which generally arises as C19H30N5O8S(C2H4O)n(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6ADW90R16. European Medicines Agency schedules Certolizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25456. The term CERTOLIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, list 52.) As of Q4 2014, CERTOLIZUMAB remains US FDA's Preferred Term for this commodity. Certolizumab bears US NLM identifiers UMLS ID CL430555 and NCI Concept Code C97947. SMILES: none.
Same parent
Under 51202400 · 21Activities that produce or sell this
KBLI · 8Inherited from family 51200000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.